Zoetis Inc.

Zoetis Inc.

ZTSยทNYSE

$77.59

+1.6%
HealthcareDrug Manufacturers - General

Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company also offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites, which include fleas, ticks, and worms. It also provides other pharmaceutical products that comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives, which offer medicines to livestock. In addition, the company provides portable blood and urine analysis testing, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision animal health. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.

At a Glance

Live Snapshot
Market Cap$32.53B
EPS6.0300
P/E Ratio12.87
Earnings Date08/04/2026
3Y+52.0%
5Y+37.0%
10Y+307.0%
3Y-15.0%
5Y+31.0%
10Y+250.0%
3Y+107.0%
5Y-1620.0%
10Y+107.0%
ZTS

Zoetis Inc. Cash Conversion Engine

ZTS ยท NYSE
Net Income2.67B
Depreciation & Amortization487.00M
Stock-Based Compensation83.00M
Change in Working Capital-408.00M
Others121.00M
Capital Expenditures-621.00M
Free Cash Flow2.28B

Cash Flow Quality Analysis

FCF Conversion Rate

85.4%

Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.

CapEx Intensity

21.4%

Moderate capital requirements typical of many stable businesses. Healthy balance between reinvestment and cash generation.

FCF Growth Trend

-0.7%

Flat FCF growth. Stable but not expandingโ€”monitor for signs of business maturity or temporary headwinds.

Working Capital Impact

-$408.00M

Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.

Cash Flow Quality Insight

Asset-light with strong cash conversion: Low capital requirements combined with efficient cash generation creates significant shareholder value through dividends, buybacks, or strategic investments.

Zoetis Inc. Cash Flow Statement

ZTS โ€ข NYSE

Zoetis Inc. Cash Flow StatementDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016Dec 2015Dec 2014Dec 2013Dec 2012Dec 2011Dec 2010Dec 2009
OPERATING ACTIVITIES
2.7B
2.5B
2.3B
2.1B
2B
1.6B
1.5B
1.4B
862M
819M
339M
587M
503M
436M
248M
111M
-101M
487M
497M
491M
465M
448M
441M
412M
308M
242M
240M
199M
204M
209M
200M
205M
185M
124M
-52M
-338M
-61M
-286M
-80M
-62M
-79M
-112M
127M
-55M
-85M
-49M
23M
-74M
65M
-68M
-334M
83M
74M
60M
62M
58M
59M
67M
53M
44M
37M
43M
32M
43M
28M
19M
16M
15M
121M
145M
31M
259M
96M
137M
46M
5M
100M
111M
376M
101M
7M
13M
77M
-90M
37M
(715M)
(892M)
(754M)
(638M)
(548M)
(418M)
(418M)
(336M)
(455M)
(408M)
(224M)
(278M)
(134M)
(276M)
(142M)
(209M)
(264M)
-408M
79M
-512M
-699M
-343M
-85M
-151M
112M
-29M
-439M
-208M
-157M
-104M
-149M
-117M
100M
357M
2.9B
3B
2.4B
1.9B
2.2B
2.1B
1.8B
1.8B
1.3B
713M
664M
626M
681M
454M
497M
254M
98M
INVESTING ACTIVITIES
-621M
-655M
-732M
-586M
-477M
-453M
-460M
-338M
-224M
-216M
-224M
-195M
-184M
-126M
-135M
-124M
-135M
-24M
(285M)
-59M
-312M
-14M
-113M
-195M
-2B
-82M
-88M
-883M
(0.0)
-4M
(0.0)
-345M
-81M
-2.3B
-7M
-5M
-4M
-9M
-12M
-27M
(460M)
(338M)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
0.0
0.0
12M
23M
44M
453M
138M
28M
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
-96M
60M
6M
1M
1M
-432M
-447M
-289M
36M
90M
-8M
8M
9M
-9M
31M
196M
568M
-748M
-315M
-777M
-883M
-458M
-572M
-504M
-2.3B
-270M
-214M
-1.1B
-187M
-179M
-135M
-449M
-9M
-1.8B
FINANCING ACTIVITIES
-3.2B
-1.9B
-1.1B
-1.6B
-743M
-250M
-626M
-698M
-500M
-300M
-203M
2M
0.0
0.0
0.0
0.0
0.0
2.3B
-3M
-1.3B
1.4B
-604M
744M
-9M
1.5B
481M
-405M
1.1B
0.0
2.6B
0.0
-143M
0.0
719M
-889M
-786M
-692M
-611M
-474M
-380M
-314M
-243M
-206M
-188M
-168M
-146M
-98M
-63M
-416M
-207M
-101M
-3.2B
-1.9B
-1.1B
-1.6B
-743M
-250M
-626M
-698M
-500M
-300M
-203M
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
-14M
-13M
24M
-49M
-45M
9M
-2M
-30M
-26M
-10M
11M
-10M
-2.7B
-15M
529M
-70M
1.2B
-1.9B
-2.7B
-3.1B
-904M
-1.9B
123M
-951M
533M
-251M
-903M
755M
-154M
-200M
-78M
-30M
-277M
1.8B
CASH FLOW SUMMARY
39M
-32M
-7M
-29M
-12M
-7M
-8M
-26M
12M
-23M
-32M
-13M
-9M
-3M
-2M
-4M
-7M
325M
-54M
-1.5B
96M
-119M
1.7B
332M
38M
837M
-427M
272M
272M
293M
238M
16M
-36M
93M
2B
2B
3.6B
3.5B
3.6B
1.9B
1.6B
1.6B
727M
1.2B
882M
610M
317M
79M
63M
99M
6M
2.3B
2B
2B
3.6B
3.5B
3.6B
1.9B
1.6B
1.6B
727M
1.2B
882M
610M
317M
79M
63M
99M
2.3B
2.3B
1.6B
1.3B
1.7B
1.7B
1.3B
1.5B
1.1B
497M
440M
431M
497M
328M
362M
130M
-37M

SEC Filings

ZTS - Filing history and reports

Filing TypeFiling DatePeriod EndingFiscal YearActions
8-K

8-K 2026

N/A

May 22, 2026
May 20, 2026
2026
8-K

8-K 2026

N/A

May 20, 2026
May 20, 2026
2026
10-Q

10-Q 2026 Q1

Q1

May 07, 2026
March 31, 2026
2026
8-K

8-K 2026

N/A

May 07, 2026
May 07, 2026
2026
DEF 14A

DEF 14A 2025

N/A

April 08, 2026
December 31, 2025
2025
10-K

10-K 2025 FY

FY

February 12, 2026
December 31, 2025
2025
8-K

8-K 2026

N/A

February 12, 2026
February 12, 2026
2026
8-K

8-K 2026

N/A

February 05, 2026
February 05, 2026
2026
8-K

8-K 2025

N/A

December 18, 2025
December 15, 2025
2025
8-K

8-K 2025

N/A

December 11, 2025
December 11, 2025
2025
Showing 1 to 10 of 258 filings